

## Index

### a

- absorption, distribution, metabolism, and excretion (ADME) 68, 71, 80, 81, 130, 168
- active site inhibitors 14, 210
- acute myelogenous leukemia (AML) 133
- acyclic (*Z*)-4-hydroxybut-2-enyloxy 159
- adhesion and degranulation-promoting adapter protein (ADAP) 3, 107
- AGC kinases 187, 190, 210
  - activity, allosteric regulation 196
  - binding modulators, potential supportive effects 209–212
  - PDK1 allosteric activators 209, 210
  - PIF pocket-directed inhibitors 210–212
  - discovery, and physiological functions 190–192
  - druggable site 212, 213
  - general medicinal chemistry aspects 213–215
  - inactive structures 197
  - mediated signaling pathways, disruption 213
  - PIF pocket-directed inhibitors 210–212
  - properties to drug development 192–199
  - allosteric mechanism 196–198
  - highly selective ligands, development potential 192, 193
  - natural HM peptide ligands, molecular interactions 193–196
  - structural plasticity 198, 199
  - small-molecule PIF pocket ligands 199–209
- A-kinase anchoring proteins (AKAPs) 3
  - allosteric inhibitors 66, 188, 189, 196, 207–210, 214
  - LFA-1/ICAM interaction 171
  - targeting PIF pocket of PKC $\zeta$  207
- allosteric kinase activators 189
- allosteric mechanisms 66, 189, 196, 198
  - allosteric modulators 193, 210
- Alzheimer's disease (AD) interactome 36, 37
- Amgen's chromenotriazolopyrimidine lead compound
  - stereochemistry optimization 139
- Amgen's chromenotriazolopyrimidine scaffold
  - *N*-alkyl substituent optimization 143
  - aryl substituents optimization 140, 141
- Amgen's piperidone ring scaffold
  - *N*-alkyl substituent optimization 145, 147
  - C3 substituent optimization 146, 147
  - lead compounds for 144
- amine groups optimization 134, 154
- amino acid 105, 109, 116, 131, 192, 211, 228, 232, 258, 261, 263, 268, 293, 297
- amphiphysin 12
- anchor-centered screening of p53/MDM2/4, hit rate validation 95, 96
- AnchorQuery chemical space, MCR scaffolds 90
- AnchorQuery search 92
  - algorithms
  - single-threaded performance 92
  - flowchart 94
- angiogenesis 259, 264, 271
- angiotensin-converting enzyme inhibitors 214
- antiangiogenic drug 268
- anti*-stereoisomer 139
- apoptotic pathway 153
- aromatic-biased compounds 89
  - drug-like properties 89
- aromaticity 75–77
- aspartimides 274
- atosiban 225–227
  - antagonist 226
- ATP-competitive drugs 200

- ATP-competitive inhibitors 187  
 ATP-competitive PLK inhibitors 299  
 autoimmune diseases 165. *See also* LFA-1/  
 ICAM interaction
- b**
- bacteria–host interspecies interactome  
 studies 33–35  
 bacteria–human interspecies  
 interactomes 40  
 – experimental approaches to identify  
 bacteria–human PPIs 40  
 – modeling bacteria–human PPIs 40, 41  
 bacteria intraspecies interactomes 37  
 – identification, high-throughput experiment  
 approaches 37, 38  
 – *Bacillus subtilis* proteins 38  
 – *Campylobacter jejuni* proteins 38  
 – *Helicobacter pylori* proteins 38  
 – *Mycobacterium tuberculosis* proteins 37, 38  
 – *Streptococcus pneumoniae* whole-cell  
 proteome 38  
 – *Treponema pallidum* interactome 38  
 – modeling intraspecies bacterial  
 interactions 39, 40  
 Bcl-2 family proteins 59  
 Bcl-2 inhibitors 75  
 BDP scaffold, optimization of  
 –  $\alpha$ -amino acid and phenyl group 134  
 – benzodiazepindione ring 135  
 – carboxylic acid 135, 137  
 – ring nitrogen 136, 138  
 4-benzimidazolyl-3-phenylbutanoic acid  
 analogs 207, 208  
 benzoazepine-2-ones 206  
 benzodiazepindione ring optimization 135  
 1,4-benzodiazepine-2,5-dione (BDP) 133  
 benzotriazol-1-yl  
 oxytripyrrolidinophosphonium  
 hexafluorophosphate 237  
 benzyl amide group, optimization and  
 exhaustive fluorine scans 156  
 biaryl sulfide core, and rings 173  
 bicyclic hydantoins 181  
 binding affinities 68, 96, 105, 116, 189, 203,  
 212, 213, 239, 300  
 binding motifs, from proteomic screens 109,  
 110  
 binding pockets 59, 60, 64, 65, 105, 130, 171,  
 189, 203, 213, 263, 276, 280  
 bioactive epitopes 281  
 biological general repository for interaction  
 datasets (BioGRID) 31
- biomolecular interaction network database  
 (BIND) 31  
 biomolecular object network databank  
 (BOND) 31  
 BIRT377 178, 180  
 Boc-protected indanyl-(*R*)-glycine 231  
 B-Raf kinase 188  
 bromophenyl moieties 132  
*Brucella melitensis* 42  
 (*S*)-*sec*-butyl analog 241  
*tert*-butyl ester 144  
*tert*-butyl group 148  
 (*R*)-*sec*-butyl isomers 246
- c**
- calcineurin binding protein 3  
 calcipressin 3  
 cancer pathogenesis 271  
 canonical interactions 272  
 carboxylic acid optimization 135, 137, 154  
 caspase 9 inhibitor 85  
 catalytic domains alignment 194  
 $\beta$ -catenin 3, 5, 6, 11  
 – complex of Tcf4 bound to 6  
 CD2-binding protein 112  
 CDKs. *See* cyclin-dependent kinases (CDKs)  
 cell adhesion receptors 259  
 cell-adhesive properties 260  
 cell-based assays 132, 137, 148, 151, 175, 178,  
 215  
 cell cycle protein kinases 291–298  
 cell-expressed integrins 260  
 central nervous system (CNS) 225, 228, 244  
 charge–charge interaction 143  
 chemical space 66, 67  
 – rationalization 67, 68  
 – visualizing 70, 71  
 chiral system 229  
 3,5-chloro system 295  
 chromenotriazolopyrimidines 137, 142  
 – cellular upregulation 142  
 – drug-like properties 139  
 – torsion 140  
 cilengitide 257, 258, 271. *See also*  
*N*-methylation  
 – design 281  
 – structure 269–271  
 – x-ray structure 265  
 cinnamide linker 171  
 c-Jun kinase inhibitor BI-78D3 188  
 clathrin-binding accessory proteins 12  
 clathrin-TD 13  
 cocrystal structure analysis 136, 148

- combinatorial chemistry methods 88, 115, 116
- computational methods
- conservation of gene neighborhood 27, 28
  - gene expression 29
  - gene fusion 29
  - integration approaches 29, 30
  - phylogenetic profiling 28, 29
  - sequence-based coevolution 29
  - structural similarity 29
- c(RGDfv)
- conformational aspects, and selectivity of c(RGDfv) 263–265
  - di-*N*-methylated analogs 272
  - peptide bond in 265
- Crk-like (CRKL) small adapter protein 110
- cyclic amines 173
- cyclic benzoazepin-2-one scaffold 206
- cyclic carbamate 236
- cyclic hexapeptides, spatial screening 262
- cyclic pentapeptides
- chemical structure 262
  - spatial screening 262
- cyclic peptides 115, 261, 276, 281
- containing the isoDGR sequence 276
  - c(phg-isoDGR-G) affinity for 278
  - c(VfdGr), inactive towards 265
  - cyclic peptide cilengitide, c(RGDf(NMe)V) 257
  - cyclic peptide of sequence RGDfV 261
  - design 276–279
  - head-to-tail 281
  - insertion of the RGD sequence 260
  - isoDGR-2C 281
  - *N*-methylation, effect of 267
  - nuclear magnetic resonance (NMR)-based solution structure 168
  - OTR antagonists 226
  - use 258
- cyclin-binding groove (CBG) 292
- structural comparison 297
- cyclin-dependent kinases (CDKs) 291
- inhibition, through cyclin groove 291–298
  - inhibitor p21 141
  - non-ATP-competitive inhibitors 301
  - through cyclin groove, inhibition 291–298
- cyclin groove inhibitors (CGIs) 291
- development 292
- cyclohexyl substituted anilines, SAR studies 179
- N*-cyclopropylmethyl derivative 144
- CYP450 isozymes 250, 252
- cytotoxicity 9
- d**
- database of interacting proteins (DIP) 31
- deamino-oxytocin 232
- delayed-type hypersensitivity model 176
- dephospho-HM peptides 191
- deuterium exchange experiments 198
- 2',4'-difluorobenzaldehyde 236
- 2,4-difluoro derivative 233
- 2,4-difluorophenyl dimethylamide 244
- 2',4'-difluorophenyl-2,5-DKP dimethylamide 238
- 3,4-difluorobenzylamine 155
- 2',4'-difluorophenyl *N,N*-dimethylamide 235
- cytochrome P450 inhibition profile 238
  - PK/pharmacodynamics comparisons 236
  - plasma concentrations 235
  - whole-cell activity 236
- dihydrobenzodioxine 173
- dihydropyrrrolizinone LFA-1 inhibitors 182
- dihydropyrrrolizinone scaffold 182
- 2,5-diketopiperazines (2,5-DKPs) 228
- 2',4'-difluorophenyl-2,5-DKP dimethylamide 22, 238
  - five- and six-membered heterocyclic 238
  - 6-indanyl-3-alkyl-7-aryl/heterocyclic-2,5-DKP oxytocin antagonists 254
  - 6-indanyl-3-isobutyl-7-aryl-2,5-DKPs, synthesis 230
  - pharmacokinetics of (3*R*,6*R*,7*R*)-2',4'-difluorophenyl-2,5-DKPs 233
  - potency 251
  - 3'-pyridyl-2,5-DKP template 246
  - (6*R* (indanyl),3*R* (*S*)-*sec*-butyl),7*R* (2',6'-dimethyl-3'-pyridyl))-2,5-DKP 252
  - *RRS* 6-indanyl-3-isobutyl-7-aryl-2,5-DKP secondary amides synthesis 230, 231
  - SAR 229
  - *sec*-butyl dimethyl substituted pyridyl (3*R*,6*R*,7*R*)-2,5-DKPs in rat and 249
  - secondary amides, synthesis 231
  - selected (3*R*,6*R*,7*R*)-2'-methyloxazole-2,5-DKPs oxytocin antagonists 242
  - tertiary amides, synthesis 237
  - x-ray crystal structures 231, 232
- dimerization 5, 110
- dimethyl oxazole 239
- 2',6'-dimethyl-3'-pyridine morpholine amide 248, 250, 252
- “disrupted in schizophrenia 1 (DISC1)” 36
- disrupt protein interactions 85–97
- druggable sites in PPIs 86, 87
  - hit rate validation of anchor-centered screening of p53/MDM2/4 95–96

- medicinal chemists, interactive modeling techniques for 93–95
  - new MCR chemistry to design PPI antagonists 89, 90
  - structure-based library design 87–89
  - virtual screening 90–93
  - distance geometry (DG) calculations 268
  - 2,5-DKPs, crystal structures
    - comparison 230–232
  - domain-mediated selectivity 113
  - drug development projects 214
  - drug discovery program 85, 114
  - druggable sites, in PPIs 86, 87
  - drug-like aryl moieties 207
  - drug-like modulators 61
  - drug target selection 114
- e**
- ECM proteins 257, 259, 275
  - electrostatic interactions 214
  - (*S*)-enantiomer 136
  - enthalpy 203, 214
  - entropy compensation effect 214
  - enzyme inhibitors 70, 72, 76, 78
  - enzyme-linked immunosorbent assay (ELISA) 155
  - epelsiban 225, 244, 250, 252, 254
  - epidermal growth factor (EGF) 2
  - Escherichia coli* 29
  - ester-containing compounds 153
  - estimated human oral absorption (EHOA) value 233
  - 1-ethoxy-2-methoxyethyl group 151
  - E3 ubiquitin ligase 129
- f**
- first-generation peptide antagonists 227
  - five-membered heterocyclic compounds, properties 241
  - five-membered heterocyclic derivatives 239–244
    - oxytocin antagonist activity/selectivity
    - vs. human vasopressin receptors 242, 243
    - *in vivo* potency and synthesis 243, 244
  - five-membered heterocyclic rings 239
  - five/six-membered heterocyclic derivatives
    - modifications 238, 239
  - flanking residues 260, 277, 278
  - flat surface pocket 213
  - flavin adenine dinucleotide (FAD) 5
  - flavinmononucleotide (FMN) 5
  - FLIP compounds 300
  - FoxO transcription factor family 3
- fragment-ligated inhibitory peptides (FLIPs) 294
  - 5,6-fused heteroaryl systems 229
- g**
- gene fusion 29
  - Genentech inhibitors, bind I-domain at MIDAS site 169
  - Gene Ontology 31
  - genomes 29
  - Glu130–Lys111 salt bridge 209
  - glycoprotein IIIa/IIb 259
  - G-protein coupled receptors (GPCR) 36, 64, 66, 225
  - Grb2-related adapter protein 2 (Grap2) 108
  - Grb2 SH3 domains 110
  - growth factor receptor-bound protein 2 (Grb2) 107
  - GSK221149A 241–243, 254
  - GTPase activators 101
- h**
- head-to-tail cyclic peptides 279
  - head-to-tail cyclized pentapeptides 277
  - hematopoietic progenitor kinase 1 (HPK1) 108
  - HIV-Nef-SH3 13
  - HIV Nef–Src homology 3 (SH3) interaction 13
  - HIV-1 viral protein 42, 43
  - HomoMINT database 37
  - host–pathogen communication 24
  - HPV E1/E2 complex 7, 8
  - human intraspecies interactomes 32, 36, 37
  - human oxytocin receptors, inhibition of oxytocin binding 248
  - human protein reference database (HPRD) 31
  - human vasopressin receptors 244, 252, 254
  - Huntington’s disease (HD) interactome 36
  - D-hydantoinase 231
  - hydrogen-bond 8, 95, 105, 109, 131, 136, 149, 177, 193, 214, 265, 270, 295, 299
    - acceptors 68, 71, 72, 90
    - donors 69, 71, 72, 214, 215, 267
  - hydrophobic
    - contact 6, 105, 108, 109, 110, 178, 213, 270
    - interactions 7, 8, 10, 116, 148, 177, 203, 215
    - pockets 106, 172, 187, 294
  - hydrophobic motif (HM) peptide 190
  - 3-hydroxycyclopentpoxy derivative 158
  - 3-hydroxyisoindolinones 156

## i

- ICAM/LFA compounds 80
- ICAM1988 structures 169
- IC-747 bound in IDAS site 176
- IC50s structure 172
- I-domain allosteric site (IDAS) 166
- I-domain Rossmann fold 166
- IFN- $\alpha$ /IFNAR complex 8, 9
- imatinib 188
- imidazoimidazolone scaffold 180
- 6-indanyl-2,5-DKPs, two-stage synthesis 231
- indanyl-2,5-DKP template 228
- 6-indanyl-3-isobutyl-7-aryl-2,5-DKPs synthesis 230
- inducible nitric oxide synthase (iNOS) homodimer 5
- inhibition strategies, peptide and peptoid inhibitors 114–119
  - combinatorial approaches 115, 116
  - constrained peptides 118
  - peptide dimers 116, 117
  - peptide ligands 114, 115
  - N-substituted peptoids 118, 119
- inhibitors 64
  - vs. ADME/Tox properties 71–74
  - vs. aromaticity 75–77
  - case study 68–80
  - vs. chemical complexity 77
  - chemical space visualization 70, 71
  - chemical synthesis 64
  - distribution 69
  - enzyme datasets 78
  - identification of 10–13
  - individual vertical box-plot 74
  - interaction types 64, 65
  - interface properties 65
  - interpretable molecular descriptors 69
  - leap into iPPI chemical space 66–68
    - road to rationalization 67, 68
    - seminal works 66, 67
  - vs. molecular shape 77–79
  - molecular weight–AlogP biplot 75
  - orthosteric vs. allosteric modulation 66
  - physicochemical properties 68
    - of PLKs 298
  - PB domain 298–301
  - vs. potency 79, 80
  - propensity 72
  - 3-75 rule 75
  - structure complexity 78
  - x-ray structures 56
- initial structure-activity relationship studies 227–230
- InParanoid database 32
- IntAct molecular interaction database (IntAct) 31
- integrins 257, 258, 271
  - binding motif, development (*See* NGR deamidation)
  - dependent process 275
  - ECM protein interactions with 258
  - inhibitors, design and development 258
  - inhibitors with therapeutic potential 258
  - isoDGR Sequence as new integrin-binding motif (*See* isoDGR Sequence)
  - receptors 260
    - structure and activation 166–168
    - I-domain Rossmann fold showing MIDAS and IDAS sites 166
- interaction, types 64, 65
- interactive modeling techniques, for medicinal chemists 93
  - AnchorQuery 94
  - flowchart 94
  - download, for secondary screening 95
  - PocketQuery server 95
  - ZINCPharmer interface 93
- interactomes 24, 32
  - human intraspecies 32, 36, 37
- interfaces
  - properties 65
  - structural features 3
- interferons (IFNs) 8
  - Arg149Ala reducing affinity of 8
- interleukin (IL)-2 12
- interpretable molecular descriptors 69
- intracellular adhesion molecule (ICAM)-1 2, 67, 165
- in vitro* functional assay 241
- in vivo* pharmacokinetics (PK) experiments 142
- in vivo* potency 235, 236, 243
- iPfam algorithms 39
- isoAsp residues, formation 274, 275
- isobutyl ester 169
- isoDGR motif 277, 278
- isoDGR Sequence 274
  - design of cyclic peptides containing isoDGR motif 276–278
  - formation of isoAsp residues 274, 275
  - inhibitory activity (IC50 nM) of head-to-tail cyclic peptides 279
  - NGR deamidation to isoDGR 275

- receptor selectivity of cyclic isoDGR peptides 279–281
- isoindolinone scaffold, optimization of
  - aryl(1) and nitrogen positions 159
  - hydroxyl and nitrogen positions 157, 158
  - hydroxyl, nitrogen, and aryl(1) positions 160
- isoleucine 232
- isonipecotic acid 174, 175, 177
- ortho*-isopropyl LFA-1/ICAM inhibitor structure 172
- isothermal titration calorimetry (ITC) 203

**j**

- JAR choriocarcinoma cells 137

**k**

- KEGG (Kyoto encyclopedia of genes and genomes) 31
- KEGG LIGAND database 41
- kinase inhibitors 67, 89, 187, 215, 292
- Kistrin protein 168

**l**

- Lck SH3 domain 111
- lead compound, from disubstituted B-ring series 175
- lead computational compounds 157
- lead oxytocin antagonist 238, 250. *See also* retosiban
  - human vasopressin receptors 250
  - *in vivo* efficacy 250
- LEDGF/HIV-IN complex 6, 7
  - crystal structure 7
- LEF (lymphoid enhancer factor) 3
- D-leucine methyl ester 231
- LFA-1/ICAM inhibition, improvement strategy 170
- LFA/ICAM inhibitors 74
- LFA-1/ICAM interaction
  - allosteric inhibitors 171
  - – Abbott/ICOS/Biogen series 171–178
  - – Boehringer Ingelheim/Tanabe Seiyaku/Bristol-Myers Squibb series 178–183
  - direct inhibition 168–170
- lipophilicity 161
- lipophilic selectivity pocket 192
- lymphocyte function-associated antigen-1 (LFA-1) 165
  - hydantoin inhibitors 180, 181
  - LFA-1/ICAM interaction, direct inhibition 168–170
  - structural change 167

**m**

- MDM2 antagonists. *See* nutlins
- melanoma inhibitor 85
- metal ion-dependent adhesion site (MIDAS) 270
  - domain 166, 167
- methylamide 239
- N*-methylation 267
  - di-*N*-methylated analogs of c(RGDV) and  $\alpha_v\beta_3$  selectivity 271–273
  - *N*-methyl scan of c(RGDV) 268–271
- methylpiperazinyl group 151
- microRNA processing 129
- mitogen-activated protein kinase (MAPK) pathway 1
- model for domain-mediated selectivity
  - via negative evolution 113
- modulators 55–61
- molecular dynamic (MD) simulations 263
- molecular shape 77–79
- molecular weight–AlogP biplot 75
- morpholine amide 250
- 2-morpholin-4-yl-ethylamine group 149
- multicomponent reaction (MCR) chemistry
  - aromatic-biased libraries, chemical diversity 91
  - to design PPI antagonists 89, 90
  - MCR scaffolds comprising AnchorQuery chemical space 90
- multipolar orthogonal interactions 215
- murine contact hypersensitivity model 168
- mutations
  - Alanine scan studies 131
  - Arg149Ala 8
  - conserved hydrophobic residues 102
  - essential RGD recognition sequence 275
  - I-like domain 166
  - PDK1 knockin 210
  - phenylalanine residues 190
  - PIF pocket 211
  - SH3 domain RT loop (R96I) 110
  - site-directed mutagenesis 231
  - T98D 106

**n**

- 2-*N*-alkyl-3-aryl-3-alkoxyisoindolinones 155
- N*/C-capped dipeptides, structure activity 296
- Nef/Fyn complex 110
- Nef protein 110
- nerve growth factor (NGF) 67
- NGR deamidation to isoDGR, yield new integrin-binding motif 275
- nipecotic acid, C-rings maintain potency 174

- nonpeptidic CDK2/cyclin A inhibitor 297
- non-PPI intraspecies bacterial and bacteria-human interspecies interactome models 41, 42
- nuclear Overhauser effect (NOE) 171
- nutlins 12, 59, 131, 133
- class of p53/MDM2 inhibitors 132
  - clinical trials 133
  - nutlin-3 bound to MDM2 60
  - optimization study 134-143, 145-147, 160
- o**
- open reading frames (ORFs) 36
- orthosteric vs. allosteric modulation 66
- OTRs. *See* oxytocin, receptors (OTRs)
- oxazole analogs 239
- oxytocin antagonists. *See also* epelsiban
- activity and selectivity 242
  - vs. human vasopressin receptors 242
  - antagonist L-368,899 227, 254
  - design 232
  - lead oxytocin antagonist 238
  - potency 247
  - comparison 253
  - intrinsic clearance 247
  - retosiban 244
  - selectivity vs. human vasopressin receptors 234, 245
  - *in vivo* efficacies 235
- oxytocins 225, 226
- active nonpeptide oxytocin antagonists 227
  - active oxytocin antagonist 227
  - agonist, structure of 226
  - antagonists (*see* oxytocin antagonists)
  - binding assay 238
  - crystal structures comparison 231, 232
  - deamino-oxytocin 232
  - inhibition of oxytocin binding 248, 249
  - receptors (OTRs) 225, 231, 234, 248, 251
  - role 226
  - and 7TM G-protein-coupled OTR 226
- p**
- p38a mitogen-activated protein kinase 188
- p53-dependent reporter assay 141
- pentapeptide inhibitors 293
- peptide-cyclin complexes, crystallographic analysis 292
- peptide inhibitor, bound to MDM2 60
- peptides
- binding experiments 111
  - biological properties 267
  - constraining 118
  - Pro-Pro consensus sequence 118
  - dimers 116, 117
  - inhibitor 61
  - interaction pockets
  - small-molecule ligands/peptidomimetics for 200
  - library 109
  - application 298
  - ligands 114, 115
  - Pro-rich peptides 117
  - representation 273
- peptidic oxytocin antagonist. *See* atosiban
- peptidomimetics 257
- strategy 296
- phage-display experiment 111
- pharmacokinetics (PK) 232-235
- profile, optimization 232
- pharmacophores 91, 199, 206, 232
- based virtual screening platform 153
  - direct matching 95
  - elements, necessary for binding 267
  - model 206
  - Pharmer pharmacophore search algorithms
  - single-threaded performance 92
  - requirements, of c(RGDfV) to bind  $\alpha_v\beta_3$  265-267
- 3-phenylglutaric acid 201
- phenyl group, optimization 134
- 7-phenyl substituted (3R,6R,7R)-2,5-DKPs 248
- phosphate pocket 195
- phosphoinositide dependent kinase 1 (PDK1) 189
- activating compounds 209
  - activators
  - pharmacophore model 204
  - allosteric activators 209, 210
  - crystal structures 198
  - role 199
- phospholipase C (PLC) 101
- PIF pocket 189, 190. *See also* AGC kinases
- advantages 189
  - binding compounds 210
  - challenges 213, 214
  - connolly surface 195
  - directed compounds 215
  - discovery and physiological functions of 190-192
  - as druggable site 212, 213
  - ligand-induced conformation 215
  - PIF pocket-directed PDK1 modulators 203-207

- properties, relevant to drug development 192–199
  - small-molecule ligands 199–209
  - small molecules targeting 191, 202
  - superimposition 197, 199
  - targeting compounds 214
  - targeting modulators, pharmacological impact 211
  - PKC $\zeta$  inhibitors 207
  - platelet receptor 257
  - pleckstrin homology (PH) domain 188
  - PLKs inhibitors, PB domain 298–301
  - p53/MDM2 antagonists
    - nongenotoxic anticancer treatments 129
    - nutlins 131–133
    - PPI characterization by cocrystal structures 130, 131
    - scaffolds with no structural biology information 155–160
  - p53/MDM2 inhibitors 132
    - crystal structures 97
    - Nutlin class 132
  - p53/MDM2 interaction 130, 131
  - PocketQuery server 95
  - polo-like kinase 1 (PLK1)
    - polobox (PB) domain 291
  - poly-Pro IIs (PPII) helix 105
  - potency 79, 80
  - PPI Hit Profiler 68
  - p21<sup>Ras</sup>-GTPase-activating protein (Ras-GAP) 114
  - p90 ribosomal S6 kinase (RSK) 189
  - “priming” kinase 192
  - principal component analysis (PCA) 67
  - proline 106, 108
  - PROLINKS database 32
  - proof-of-concept 80, 173, 227, 254
  - property-based design 232–235
  - protein-binding sites 65
  - protein, cell-adhesive properties 258
  - Protein Data Bank (PDB) 57, 86, 101, 188, 293
  - protein inhibitor 64
  - protein interaction network 210
  - protein-L-isoAsp-O-methyltransferase (PIMT) 274
  - protein kinase C-related kinase 2 (PRK2) 189
  - protein kinases 187, 200
  - protein–protein “interactome” 1
  - protein–protein modulators 56, 58, 60
    - graph 57
    - three-dimensionality 59
  - protein–protein systems 60
  - Pseudomonas aeruginosa* 3
  - PubChem BioAssay 68
  - Purkinje cell degeneration 37
  - PVKRRRLFG sequence 297
  - PxxDY motif 107
  - PxxP motifs 110
  - 3-pyridyl-2,5-DKP template 246
- q**
- quantum mechanical calculations 146
- r**
- Raf kinase inhibitory protein (RKIP) 2
  - reactome 30, 31, 36
  - “real-time” highthroughput virtual screening 86
    - of commercially available (ZINC) and biased MCR compounds 86
  - receptor binding pocket 228, 231
  - receptor MDM2 amino acids 131
  - receptor selectivity 258–260
    - of cyclic isoDGR peptides 279–281
  - REPLACE strategy 291, 293, 299, 300
    - advantages 294
    - inhibition of CDKs through cyclin groove 291–298
    - structure activity of N- and C-capped dipeptides 296
    - validation 294, 295
    - workflow 293
  - retinoblastoma (Rb) 291
  - retosiban 225, 239, 242–244, 252, 254
  - RGD-based peptides 257
  - RGD motif 168, 258, 259, 260, 262, 264, 270
  - RGD peptides, conformations 281
  - RGD Sequence 258, 261
    - insertion in disulfide cyclized peptide 260
  - rhabdomyosarcoma (RMS) 152
  - rigid three-dimensional scaffold, benefit 59
  - ring nitrogen, optimization 136, 138
  - “Rosetta stone” protein 29
  - (3*R*,6*R*,7*R*)-2',4'-difluorophenyl-2,5-DKPs, pharmacokinetics 233
  - (3*R*,6*R*,7*R*)-2'-methyloxazole-2,5-DKPs oxytocin antagonists 242
  - RRR synthesis 231
  - RRS 6-indanyl-3-isobutyl-7-aryl-2,5-DKP secondary amides synthesis 231
  - “Rule of Five” (RO5) 67, 71, 72, 74, 79, 80
    - RO5 rule vs. iPPIs and enzyme inhibitors 71



- RO5 states 71
- RxxK motif, epitopes 108, 109
- S**
- Salmonella typhimurium* 42
- salt bridges 279
- scaffold hopping domain 91
- scaffolds, with no structural biology information 155–160
- selective OTR antagonist 242
- serum and glucocorticoid-induced protein kinase (SGK) 189
- seven-transmembrane (7TM) G-protein-coupled receptors 225
- SH3-containing Hrs-binding protein 108
- SH2 domain-containing leukocyte protein 109
- SH3 domains 111
- signaling proteins 111
- signal transducing adapter molecule (STAM) 108
- six-membered heterocyclic derivatives 244–252
  - 2',6'-dimethyl-3'-pyridine morpholine amide 77 evaluation 250–252
  - dimethylpyridyl (*S*)-sec-butyl amides 246–250
  - lead compounds comparison 252, 253
  - lead oxytocin antagonist epelsiban 77 252
  - monosubstituted pyridyl isobutyl derivatives 246
- SJSA-1 xenograft model 148
- small-molecule drug candidates 63
- small-molecule inhibitors 4, 10, 11, 12, 86, 94, 119–121, 165, 297
- small-molecule inhibitor starting points (SMISPs) 87
  - density plot 88
  - residues 87
- small-molecule ligand 211
- small-molecule/MDM2 cocrystal structures, alignment 149
- small-molecule modulators 202
- small-molecule–peptide hybrids 301
- small-molecule PIF pocket ligands 199–209
  - allosteric inhibitors 207–209
  - PDK1, allosteric activators and PPI inhibitors 199, 200
  - pharmacophore-based screening approaches 200–202
  - PIF pocket-directed PDK1 modulators 203–207
- small-molecule SH3 inhibitors 121
- solid-phase enzymes 229
- solid-phase peptide synthesis (SPPS) 274
- solvent-accessible surface area (SASA) 65, 87
- spatial index 91
- spatial screening in cyclic RGD peptides 261–263
- specificity-determining loop (SDL) 279
- spectrin
  - hydrophobic cores 104
  - three-dimensional structure 101
- spirocyclic hydantoins 181
  - second-generation 182
- spirooxindole scaffold
  - *N,N*-dimethylamine moiety optimization 152
  - phenyl ring, optimization 151
- spontaneous tumor generation 129
- Src family kinases 111
- Src homology 3 (SH3) domain
  - Abl SH3 domain 106
  - binding motifs 104–111
    - classical binding motifs 104–107
    - from proteomic screens 109, 110
    - RxxK motif 108, 109
    - tertiary interactions 110, 111
    - tyrosine-containing motifs 107, 108
  - binding of 2-aminoquinoline to Tec SH3 domain 120
  - as drug targets 101
  - PPII helix binding to 119
  - selectivity 111–114
  - sequence alignment of series 103
  - small-molecule inhibitors 119–121
  - structure 101, 102
  - variability 102–104
  - x-ray structure 102
- Src kinase-associated protein 107
- staphylococcal enterotoxin B (SEB)-induced IL-2 production 178
- steric restrictions 159
- STRING database 32, 33
- structure–activity relationship (SAR) studies 131, 168, 189, 292
- structure-based library design 87–89
- substituted aryl (3*R*,6*R*,7*R*)-2,5-DKPs oxytocin antagonists 229
- N*-substituted peptoids 118
- 6'-substituted-3'-pyridyl derivative 244
- substrate-binding interactions 292
- substrate phosphorylation assays 204
- subtype-specific regulatory mechanisms 188

- sulfone substituted
  - imidazoimidazolones 181
- synaptojanin 12
- synthetic peptides 259
  
- t**
- tautomeric isomerization 142
- Tcf (Tcell factor) 3
- Tcf4 Complex 5, 6
- template synthesis 227–230
- tertiary amides synthesis 236–238
- tetrahydroisoquinoline (THIQ)-based LFA-1 antagonists 170
- tetrapeptide Arg–Gly–Asp–Ser (RGDS) 258
  - hypotheses 260
  - identification of RGD motif 259
- thermoFluor fluorescence polarization (FP) assay 133
- thioglycollate-induced murine peritonitis model 170
- three-dimensional structures
  - of cilengitide 269
  - of full-length proteins 211
  - of MDM2 and MDMX 130
  - of protein–protein modulator 59
  - Rossmann fold 166
  - of spectrin and Src SH3 domains 101
  - x-ray structure 56, 58
- 7TM G-protein-coupled OTR 226
- transcription factor 3, 5
  - like Sp1 and Elk 2
  - p53 160
- trifluoroacetic acid 231
- Trp/Met/Phe clusters 65
- tumor necrosis factor (TNF)- $\alpha$  9
- tumor suppressor protein p53 129
- tyrosine-containing motifs 107, 108
  
- u**
- ubiquitin ligases 211
- ubiquitin–proteasome pathway 130
- Ugi four-component scaffold, optimization
  - exhaustive fluorine scans of benzyl amide group 156
  - isocyanide, amine, and carboxylic acid groups 154
- Ugi reaction 133, 153, 228, 231, 236, 254
- unsaturation index descriptor (Ui) 76
  
- v**
- Van der Waals interactions 131, 134, 140, 146, 193, 212
- vasopressin receptors 225, 227, 228, 234, 235, 241, 242, 244, 254
- Veber descriptors 72–74
- Veber rule 72
- virtual screening strategies 90–93, 214
- virulence factors synthesis 104
- virus–human interspecies interactomes 42, 43
- von Willebrand factor 68, 259
  
- w**
- Wilcoxon test 57, 58, 60
- Wnt activation 5
  
- x**
- X-linked inhibitor of apoptosis protein (XIAP) 70, 73, 212, 213
- X-ray crystallography 178, 180, 182, 183, 188
  
- z**
- ZINC database 93
- ZINCPharmer interface 93